Document Type
Thesis
First Faculty Advisor
Bryan Knapp
Second Faculty Advisor
Julie Volkman
Keywords
pharmaceutical industry; mental health; prescription practices; healthcare ethics
Publisher
Bryant University
Rights Management
CC-BY-NC-ND
Abstract
This paper explores the relationship pharmaceutical companies have with the overprescription of mental health medication, highlighting unethical marketing practices and their impact on prescription patterns. Previous literature addresses unethical pharmaceutical company marketing strategies, relationships within the field, and cost differences. This study includes qualitative insights from professionals in the field. Interviews conducted collected information that showed the prevalence of mental health illnesses, how treatments are prescribed, and the extent of pharmaceutical influence. Initial findings suggest a significant push for medication as it is the most common treatment method for mental health illnesses. This study highlights pharmaceutical companies' profit-driven motives and their effects on individuals' mental health treatments.
Included in
Chemicals and Drugs Commons, Mental and Social Health Commons, Pharmacy and Pharmaceutical Sciences Commons
Comments
This thesis was completed as part of an undergraduate honors program in fulfillment of the degree requirements at Bryant University. It was aimed to explore the ethical and societal implications of pharmaceutical company influence on mental health medication prescriptions.